[1] TERPOS E, MOUGIOU A, KOURAKLIS A. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes:a phase II trial in 281 patients. 2002(1). doi:10.1046/j.1365-2141.2002.03583.x
[2] CLAVIO M, NOBILI F, BALLEARI E. Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes:a preliminary report. 2004(2). doi:10.1046/j.0902-4441.2003.00183.x
[3] RIGOLIN G M, PORTA M D, BIGONI R. rHuEPO administration in patients with low-risk myelodysplastic syndromes:evaluation of erythroid precursors'response by fluorescence in situ hybridization on May-Grunwald-Giemsa-Stained bone marrow samples. 2002(3). doi:10.1046/j.1365-2141.2002.03867.x
[4] CHUNCHARUNEE S, INTRAGUMTORNCHAI T, CHAIMONGKOL B. Treatment of myelodysplastic syndrome with low-dose human granulocyte colony-stimulating factor:a multicenter study. 2001(2). doi:10.1007/BF02981996
[5] ROSSI H A, O'DONNELL J, SARCINELLI F. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome. 2002(3). doi:10.1038/sj.leu.2402368
[6] HAST R, HELLSTROM-LINDBERG E, OHM L. No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes:better outcome in patients with less proliferative disease. 2003(9). doi:10.1038/sj.leu.2403035
[7] FERRAJOLI A, TALPAZ M, KURZROCK R. Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation, 1998(3-4)
[8] MUSTO P, SANPAOLO G, D'ARENA G. Adding growth factors or interleukin-3 to erythrpoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone, 2001(1)
[9] NAND S, STOCK W, STIFF P. A phase II trial of interleukin-2 in myelodysplastic syndromes. 1998(1). doi:10.1046/j.1365-2141.1998.00672.x
[10] PAN L, OHNISHI K, ZHANG W J. In vitro IL-12 treatment of peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes:increase in cytotoxicity and reduction in WT1 gene expression. 2000(9). doi:10.1038/sj.leu.2401872
[11] DEEG H J, GOTLIB J, BECKHAM C. Soluble TNF receptor fusion protein(etanercept) for the treatment of myelodysplastic syndromes:a pilot study. 2002(2). doi:10.1038/sj.leu.2402356
[12] STASI R, AMADORI S. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. 2002(2)
[13] HOFMANN W K, GANSER A, SEIPELT G. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid,interferon alpha,and granulocyte colony-stimulating factor. 1999(3). doi:10.1007/s002770050488
[14] 刘秋玲, 马伏英, 杨玉兰. 基因重组干扰素-γ治疗儿童骨髓增生异常综合征的临床研究. 中国小儿血液2001(1). doi:10.3969/j.issn.1673-5323.2001.01.009
[15] KILLICK S B, MUFTI G, CAVENAGH J D. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. 2003(4). doi:10.1046/j.1365-2141.2003.04136.x
[16] SAUNTHARARAJAH Y, NAKAMURA R, NAM J M. HLA-DR15(DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome, 2002(5)
[17] STEENSMA D P, DISPENZIERI A, MOORE S B. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemia patients with myelodysplastic syndrome. 2003(6)
[18] SELLERI C, MACIEJEWSKI J P, CATALANO L. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia:in vitro and in vivo studies. 2002(9). doi:10.1002/cncr.10915
[19] SHIMAMOTO T, OHYASHIKI K. Immunosuppressive treatments for myelodysplastic syndromes. 2003(4). doi:10.1080/1042819021000055345
[20] NAKAMURA S, OHNISHI K, YOSHIDA H. Retrovirus-mediated gene transfer of granulocyte colony-stimulating factor receptor (G-CSFR) cDNA into MDS cells and induction of their differentiation by G-CSF, 2000(2)
[21] MATTHES T W, KINDLER V, LEUBA F. Optimized lentiviral transduction of erythroid precursors from healthy adults and patients with myelodysplastic syndromes. 2002(7). doi:10.1038/sj.leu.2402527 |
